TRENDS

Strong April-June Sales Show Market Shift to SGLT2/DPP-4 Combos

August 8, 2018
By Reiji Anasako Fixed-dose combination drugs of SGLT2 inhibitors and DPP-4 inhibitors delivered bullish sales in April-June, with two approved products in Japan both seen likely to outstrip their full-year forecasts through March 2019, illustrating the SGLT2 market’s shift to…

To read the full story

TRENDS

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Takashi Ebisawa

A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…